Evidence map›Paper›PMID 42725854›Full record

ArticleJournal of cellular and molecular medicine2026

SFRP2 Potentiates Metastasis of Colon Cancer by Enhancing Snai1 Protein Stability via USP11.

Yanshen Kuang, Xin Liu, Mu Ke, Zhijie Chang, Baoqing Jia, Bing Li, Honggang Qian

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanshen KuangDepartment of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.ORCID https://orcid.org/0009-0007-3635-6075
Xin LiuDepartment of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Mu KeDepartment of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Zhijie ChangState Key Laboratory of Membrane Biology, School of Medicine, National Engineering Laboratory for Anti-Tumor Therapeutics, Tsinghua University, Beijing, China.
Baoqing JiaDepartment of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-7006-0741
Bing LiDepartment of General Surgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Honggang QianKey Laboratory of Carcinogenesis and Translational Research, Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital, Beijing, China.ORCID https://orcid.org/0009-0006-6899-164X

Funding

National Natural Science Foundation of China 82173355
6 · The paper itself

Abstract

Metastatic colon cancer remains a significant clinical challenge, often associated with poor patient prognosis. Recent studies have identified the secreted frizzled-related protein 2 (SFRP2) as a key player in this malignancy, showing its overexpression in metastatic cases. This research aimed to elucidate the molecular mechanisms by which SFRP2 influences colon cancer progression. We employed in vitro assays to assess the effects of SFRP2 on cell migration and invasion, revealing that SFRP2 significantly enhances these processes without affecting cell proliferation. Mechanistically, we found that SFRP2 interacts with Snai1, a transcription factor known to promote epithelial-mesenchymal transition (EMT), thereby stabilizing Snai1 protein levels. Furthermore, SFRP2 was shown to inhibit Snai1 ubiquitination through the deubiquitinase USP11, leading to increased Snai1 activity. Notably, Snai1 also positively regulates SFRP2 transcription, establishing a feedback loop that amplifies their expression. Our findings indicate that the SFRP2-Snai1 axis promotes colon cancer cell migration and invasion via the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway. In vivo experiments further confirmed that the SFRP2-Snai1 interaction significantly enhances metastatic potential. Collectively, these results suggest that targeting the SFRP2-Snai1 signalling pathway may provide a novel therapeutic strategy for metastatic colon cancer.

Indexed as

Colonic NeoplasmsMembrane ProteinsSnail Family Transcription FactorsAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMiceMice, NudeNeoplasm InvasivenessNeoplasm MetastasisPhosphatidylinositol 3-KinasesProtein StabilityMembrane ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSecreted Frizzled-Related ProteinsSFRP2 protein, humanSNAI1 protein, humanSnail Family Transcription FactorsTOR Serine-Threonine Kinasescolon cancermetastasisPI3K/AKT/mTORSFRP2Snai1USP11

Identifiers

PMID42725854
PMCPMC13564241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.